Effect of nasal corticosteroid on cacosmia after COVID-19
| Autor: | Usama Taya, Ahmed Gaber AbdElraheem, Nehad Hassan Abdelrahman |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | SVU - International Journal of Medical Sciences, Vol 5, Iss 2, Pp 461-469 (2022) |
| Druh dokumentu: | article |
| ISSN: | 2735-427X 2636-3402 |
| DOI: | 10.21608/svuijm.2022.149179.1336 |
| Popis: | Background: Olfactory disorders may be an isolated symptom of (COVID-19) infection. Multiple treatment modalities have been attempted to treat them. Objectives: compare the effect of nasal corticosteroid on COVID-19 positive patients aiming to decrease the duration of olfactory qualitative, quantitative and residual abnormalities as cacosmia with those who hadn't taken nasal corticosteroid Patient and methods: This study included 200 patients who presented to the Otorhinolaryngology Department, divided into equal two groups: Group1 (treated group) All patients were given two sprays (50 mcg of mometasone furoate in each spray) in each nostril twice daily (total daily dose of 400 mcg). Group 2 (untreated group) those who weren’t administered nasal corticosteroid or systemic corticosteroid in anosmia treatment. Result: Anosmia in group 1 improved by 61% in the first week,83% in the second week,100 % after one month, and regular follow-up was done for 6 months while in group 2 improvement was 42% in the first week,59% in the second week,73% after one month .In group 2 out of 100 patients 30 patients complained of cacosmia after initial anosmia 3 of them reported improving smell after 1 week then 2 weeks later cacosmia appeared and none of them were improved within the 6 months of follow up with significant p-value between 2 groups |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|